Wissenszentrum

Tiefgehende Analysen für Pharma-Fachleute

Hintergründe zu Forschung, Innovation und Markttrends — der Kontext hinter den Schlagzeilen, geschrieben für Menschen aus der Branche.

58 Artikel im Wissenszentrum
Computer System Validator (CSV) vs. Computer System Assurance (CSA): What Are the Main Differences?Forschung

Computer System Validator (CSV) vs. Computer System Assurance (CSA): What Are the Main Differences?

Guide to Computer System Validation (CSV) vs Computer Software Assurance (CSA) in pharma with key differences and risk-based approach.

Vaibhavi M.10. Apr. 2026
PROTACs and Molecular Glues: How Targeted Protein Degradation Is Redefining Drug DiscoveryForschung

PROTACs and Molecular Glues: How Targeted Protein Degradation Is Redefining Drug Discovery

How PROTACs and molecular glues are redefining drug discovery through targeted protein degradation strategies.

Mrudula Kulkarni13. Feb. 2026
Neuroinflammation As A Target Class: The New Frontier In CNS Drug DevelopmentForschung

Neuroinflammation As A Target Class: The New Frontier In CNS Drug Development

Why neuroinflammation is emerging as a major target class reshaping CNS drug development and neurology research.

Vaibhavi M.13. Feb. 2026
Senolytics and Microbiome Modifiers Two Quiet Levers Reshaping the Biology of AgeingForschung

Senolytics and Microbiome Modifiers Two Quiet Levers Reshaping the Biology of Ageing

How senolytics and microbiome modifiers are reshaping ageing biology by targeting inflammation, senescence, and system-level decline.

Mrudula Kulkarni12. Feb. 2026
Psychedelic-Assisted Therapies: How Science Is Re-Exploring A Controversial Class Of MedicinesForschung

Psychedelic-Assisted Therapies: How Science Is Re-Exploring A Controversial Class Of Medicines

How psychedelic-assisted therapies are being re-explored to treat depression, PTSD, and addiction through science-led care.

Vaibhavi M.12. Feb. 2026
Engineered Microbes for APIsForschung

Engineered Microbes for APIs

How engineered microbes are quietly reshaping API manufacturing through biology, fermentation, and smarter, more resilient pharma production.

Mrudula Kulkarni27. Jan. 2026
GVP Module VI: An OverviewForschung

GVP Module VI: An Overview

A clear overview of GVP Module VI, explaining ICSR requirements, timelines, and EudraVigilance reporting in the EU.

Vaibhavi M.20. Jan. 2026
GVP As A Growth Strategy: Turning Safety Data Into Competitive AdvantageForschung

GVP As A Growth Strategy: Turning Safety Data Into Competitive Advantage

How Good Pharmacovigilance Practices are evolving from compliance into a strategic growth and trust-building function in pharma.

Vaibhavi M.20. Jan. 2026
Advantages and Limitations of Non-Viral Delivery SystemsForschung

Advantages and Limitations of Non-Viral Delivery Systems

A strategic look at non-viral drug delivery systems, their advantages, limitations, and growing role in RNA, gene, and precision therapies.

Mrudula Kulkarni19. Jan. 2026
From Human Inspection To Machine Vision: The Future Of AI-Powered Contamination Detection In PharmaForschung

From Human Inspection To Machine Vision: The Future Of AI-Powered Contamination Detection In Pharma

AI vision systems are reshaping pharma quality control by detecting contamination faster, improving consistency, and strengthening compliance.

Simantini Singh Deo24. Dez. 2025
The Antibiotic Resistance: Zosurabalpin And The War On SuperbugsForschung

The Antibiotic Resistance: Zosurabalpin And The War On Superbugs

Zosurabalpin is a first-in-class antibiotic targeting Gram-negative superbugs and offering new hope against antimicrobial resistance.

Vaibhavi M.22. Dez. 2025
Alzheimer’s Breakthrough Pipelines In The Pharmaceutical IndustryForschung

Alzheimer’s Breakthrough Pipelines In The Pharmaceutical Industry

Alzheimer’s drug pipelines are evolving as amyloid antibodies, oral agents, and precision trials redefine disease-modifying strategies.

Vaibhavi M.22. Dez. 2025